ONZETRA^® Xsail^® (sumatriptan nasal powder)

In September 2019, Optinose announced a License Agreement with Currax Pharmaceuticals which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico.

Please see Instructions for Use, Important Safety Information, and full Prescribing Information at www.ONZETRAHCP.com.